Wockhardt (WOCKPHARMA) Q1 24/25 earnings summary

Executive summary

• Standalone revenue from operations for the quarter ended June 30, 2024, was ₹352 crore, with total income at ₹379 crore, showing a significant increase from ₹251 crore and ₹257 crore, respectively, in the same quarter last year.

• Consolidated revenue from operations for the quarter was ₹739 crore, up from ₹644 crore in the same quarter last year.

• Both standalone and consolidated results were reviewed and approved by the Board on August 9, 2024, and subjected to limited review by statutory auditors.

Financial highlights

• Standalone net profit after tax for the quarter was ₹6 crore, compared to a loss of ₹115 crore in the same quarter last year.

• Consolidated net loss after tax was ₹16 crore, an improvement from a loss of ₹136 crore in the same quarter last year.

• Standalone basic and diluted EPS for the quarter was ₹0.39, compared to negative ₹8.01 in the prior year quarter.

• Consolidated basic and diluted EPS was negative ₹0.95, compared to negative ₹9.28 in the same quarter last year.

Outlook and guidance

• The company continues to focus exclusively on the pharmaceutical business segment.